GH - ゲノミック・ヘルス (Guardant Health Inc.) ゲノミック・ヘルス

 GHのチャート


 GHの企業情報

symbol GH
会社名 Genomic Health Inc (ゲノミック・ヘルス)
分野(sector)   
産業(industry)   
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Guardant Health Inc. is a United States-based company that engages in non-invasive cancer genomic sequencing. The Company is focused on developing diagnostic technologies that can transform cancer from a silent killer into a manageable disease. The Company engages in next-generation sequencing single-cell genomics and cancer diagnostics. The Company offers Guardant360 which is a biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options. The 73-gene blood test is used in advanced cancer patients with visceral solid tumor cancers or metastases and interrogates all four types of genomic alterations. The test prevents repeat invasive biopsies when cancer has progressed or recurred despite treatment or when an initial biopsy is unobtainable or has insufficient tissue. It is the circulating tumor DNA (ctDNA) test that includes all somatic genomic targets in a single test.   ゲノミック・ヘルスは米国でがんの個別化治療のためのゲノム解析(遺伝子検査)を行う。侵潤性乳がん、結腸がん、前立腺がん用の腫瘍の大きさ、悪性度、再発性、化学療法の効果性などの情報を提供するオンコタイプDX検査を行う。また、他のがんに対するオンコタイプDX検査の臨床研究を行う。   
本社所在地 301 Penobscot Drive Redwood City CA 94063 USA
代表者氏名 AmirAli Talasaz アミアリタラサス
代表者役職名 President Chief Operating Officer Director
電話番号 +1 650-290-7575
設立年月日 36739
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 863人
url www.genomichealth.com
nasdaq_url https://www.nasdaq.com/symbol/gh
adr_tso
EBITDA EBITDA(百万ドル) ー
終値(lastsale) 29.55
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 357.621
売上高 売上高(百万ドル) --
企業価値(EV) 企業価値(EV)(百万ドル) 3294.422
当期純利益 当期純利益(百万ドル) --
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Guardant Health Inc revenues increased 93% to $36.1M. Net loss applicable to common stockholders decreased 13% to $35.5M. Revenues reflect United States segment increase of 77% to $29.5M International segment increase from $2.1M to $6.6M. Lower net loss reflects G/L on early Exting of lease relat debt decrease from $5.1M (expense) to $0K Interest Exp-Net of Capitalized Interest decrease of 69% to $648K (expense).

 GHのテクニカル分析


 GHのニュース

   Liquid Biopsy Market On Target to Reach $3,805 Million by 2023, at a CAGR of 28.9% | Trovagene Inc., Guardant Health Inc  2021/03/03 12:29:16 OpenPR
Rise in demand for non-invasive, safe procedures, increase in prevalence of cancer, and benefits over traditional test procedures would drive the growth of the global liquid biopsy industry. The report offers detailed analyses of the key winning strategies, market dynamics,
   Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers  2021/03/02 13:05:00 Business Wire
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) has CE-marked Guardant360® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). The test is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib). The Guardant360 CDx test off
   Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021  2021/02/24 21:05:00 Business Wire
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2020. Recent Highlights Revenue of $78.3 million for the fourth quarter and $286.7 million for the full year of 2020, representing 25% and 34% increases, respectively, over the co
   Guardant Health to Participate in Upcoming Investor Conferences  2021/02/17 21:03:00 Business Wire
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following virtual investor conferences. 10th Annual SVB Leerink Global Healthcare Conference Fireside Chat on Friday, February 26th at 1:20 p.m. Pacific Time / 4:20 p.m. Eastern Time Cowen 41st Annual Health Care Conference Fireside Chat on Tuesday, March 2nd at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time Interested partie
   Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer  2021/02/16 13:05:00 Business Wire
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced the availability of Guardant Reveal™, the first blood-only liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw. The first-of-its-kind commercial test improves the management of early-stage colorectal cancer (CRC) patients by detecting circulating tumor DNA (ctDNA) in blood after surgery to identify patients with residual disease w
   Liquid Biopsy Market On Target to Reach $3,805 Million by 2023, at a CAGR of 28.9% | Trovagene Inc., Guardant Health Inc  2021/03/03 12:29:16 OpenPR
Rise in demand for non-invasive, safe procedures, increase in prevalence of cancer, and benefits over traditional test procedures would drive the growth of the global liquid biopsy industry. The report offers detailed analyses of the key winning strategies, market dynamics,
   Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers  2021/03/02 13:05:00 Business Wire
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) has CE-marked Guardant360® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). The test is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib). The Guardant360 CDx test off
   Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021  2021/02/24 21:05:00 Business Wire
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2020. Recent Highlights Revenue of $78.3 million for the fourth quarter and $286.7 million for the full year of 2020, representing 25% and 34% increases, respectively, over the co
   Guardant Health to Participate in Upcoming Investor Conferences  2021/02/17 21:03:00 Business Wire
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following virtual investor conferences. 10th Annual SVB Leerink Global Healthcare Conference Fireside Chat on Friday, February 26th at 1:20 p.m. Pacific Time / 4:20 p.m. Eastern Time Cowen 41st Annual Health Care Conference Fireside Chat on Tuesday, March 2nd at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time Interested partie
   Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer  2021/02/16 13:05:00 Business Wire
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced the availability of Guardant Reveal™, the first blood-only liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw. The first-of-its-kind commercial test improves the management of early-stage colorectal cancer (CRC) patients by detecting circulating tumor DNA (ctDNA) in blood after surgery to identify patients with residual disease w
   Guardant Health to Participate in Upcoming Investor Conferences  2021/02/17 21:03:00 Business Wire
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following virtual investor conferences. 10th Annual SVB Leerink Global Healthcare Conference Fireside Chat on Friday, February 26th at 1:20 p.m. Pacific Time / 4:20 p.m. Eastern Time Cowen 41st Annual Health Care Conference Fireside Chat on Tuesday, March 2nd at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time Interested partie
   Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer  2021/02/16 13:05:00 Business Wire
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced the availability of Guardant Reveal™, the first blood-only liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw. The first-of-its-kind commercial test improves the management of early-stage colorectal cancer (CRC) patients by detecting circulating tumor DNA (ctDNA) in blood after surgery to identify patients with residual disease w
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   Guardant Health : to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021 | MarketScreener  2021/02/04 21:04:01 MarketScreener
Guardant Health, Inc. , a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 24,… | February 4, 2021
   Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021  2021/02/04 21:03:00 Business Wire
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 24, 2021. Company management will be webcasting a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanth

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ゲノミック・ヘルス GH Guardant Health Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)